{
    "nctId": "NCT00679211",
    "briefTitle": "A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer",
    "officialTitle": "A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 110,
    "primaryOutcomeMeasure": "Percentage of Participants With an Objective Response as Assessed Through Independent Radiologic Review",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed study-specific Informed Consent Form(s)\n* Age \u2265 18 years\n* Histologically documented breast cancer\n* HER2-positive disease\n* Metastatic breast cancer\n* Disease progression on the last chemotherapy regimen received in the metastatic setting\n* Prior treatment with an anthracycline, trastuzumab, a taxane, lapatinib, and capecitabine in the neoadjuvant, adjuvant, locally advanced, or metastatic setting and prior treatment with at least two lines of therapy (a line of therapy can be a combination of two agents or single-agent chemotherapy) in the metastatic setting\n* At least two lines of anti-HER2 therapy must have been given in the metastatic setting as monotherapy or combined with chemotherapy or hormonal therapy. The HER2-targeted agent can include trastuzumab, lapatinib, or an investigational agent with HER2-inhibitory activity.\n* A minimum of 6 weeks of trastuzumab for the treatment of metastatic disease is required\n* Patients must have had at least 14 days of exposure in the metastatic setting to lapatinib and capecitabine (given together or separately) unless they were intolerant of lapatinib and/or capecitabine\n\nExclusion Criteria:\n\n* Chemotherapy \u2264 21 days before enrollment\n* Trastuzumab \u2264 21 days before enrollment\n* Hormone therapy \u2264 7 days before enrollment\n* Granulocyte-stimulating agent \\< 14 days before enrollment\n* Investigational therapy \u2264 28 days before enrollment\n* Previous radiotherapy for treatment of metastatic breast cancer \u2264 21 days before enrollment\n* Brain metastases that are untreated, symptomatic, or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastases within 3 months of the first study treatment\n* History of intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins\n* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin \\> 500 mg/m\\^2; Epirubicin \\> 900 mg/m\\^2; Mitoxantrone \\> 120 mg/m\\^2 and idarubicin \\> 90 mg/m\\^2\n* Peripheral neuropathy of Grade \u2265 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0\n* History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma\n* Current unstable angina\n* History of symptomatic congestive heart failure (CHF), or ventricular arrhythmia requiring treatment\n* History of myocardial infarction within 6 months of enrollment\n* Left ventricular ejection fraction (LVEF) \\< 50% within 28 days of enrollment\n* History of decreased LVEF to \\< 50% or symptomatic CHF with previous adjuvant trastuzumab treatment\n* Severe dyspnea at rest due to complications of advanced malignancy or requiring current continuous oxygen therapy\n* Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)\n* Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during the course of study treatment\n* Current pregnancy or lactation\n* Current known infection with human immunodeficiency virus (HIV), active hepatitis B, and/or hepatitis C virus\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}